158 related articles for article (PubMed ID: 19347289)
1. Molecular basis of histone deacetylase inhibitors as new drugs for the treatment of inflammatory diseases and cancer.
Glauben R; Siegmund B
Methods Mol Biol; 2009; 512():365-76. PubMed ID: 19347289
[TBL] [Abstract][Full Text] [Related]
2. HDAC inhibitors in models of inflammation-related tumorigenesis.
Glauben R; Sonnenberg E; Zeitz M; Siegmund B
Cancer Lett; 2009 Aug; 280(2):154-9. PubMed ID: 19101082
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors: multifunctional anticancer agents.
Liu T; Kuljaca S; Tee A; Marshall GM
Cancer Treat Rev; 2006 May; 32(3):157-65. PubMed ID: 16516391
[TBL] [Abstract][Full Text] [Related]
4. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.
Liu T; Liu PY; Tee AE; Haber M; Norris MD; Gleave ME; Marshall GM
Eur J Cancer; 2009 Jul; 45(10):1846-54. PubMed ID: 19342222
[TBL] [Abstract][Full Text] [Related]
5. A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways.
Hwang JJ; Kim YS; Kim MJ; Jang S; Lee JH; Choi J; Ro S; Hyun YL; Lee JS; Kim CS
Anticancer Drugs; 2009 Oct; 20(9):815-21. PubMed ID: 19644355
[TBL] [Abstract][Full Text] [Related]
6. Targeting histone deacetylases for the treatment of cancer and inflammatory diseases.
Huang L
J Cell Physiol; 2006 Dec; 209(3):611-6. PubMed ID: 17001696
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases.
Riester D; Hildmann C; Schwienhorst A
Appl Microbiol Biotechnol; 2007 Jun; 75(3):499-514. PubMed ID: 17377788
[TBL] [Abstract][Full Text] [Related]
8. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
Frew AJ; Johnstone RW; Bolden JE
Cancer Lett; 2009 Aug; 280(2):125-33. PubMed ID: 19359091
[TBL] [Abstract][Full Text] [Related]
9. New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity.
Perrino E; Cappelletti G; Tazzari V; Giavini E; Del Soldato P; Sparatore A
Bioorg Med Chem Lett; 2008 Mar; 18(6):1893-7. PubMed ID: 18294844
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?
Blanchard F; Chipoy C
Drug Discov Today; 2005 Feb; 10(3):197-204. PubMed ID: 15708534
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications.
Fantin VR; Richon VM
Clin Cancer Res; 2007 Dec; 13(24):7237-42. PubMed ID: 18094401
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
Emanuele S; Lauricella M; Tesoriere G
Int J Oncol; 2008 Oct; 33(4):637-46. PubMed ID: 18813776
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni.
Dubois F; Caby S; Oger F; Cosseau C; Capron M; Grunau C; Dissous C; Pierce RJ
Mol Biochem Parasitol; 2009 Nov; 168(1):7-15. PubMed ID: 19538992
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors induce growth inhibition, cell cycle arrest and apoptosis in human choriocarcinoma cells.
Takai N; Ueda T; Nishida M; Nasu K; Narahara H
Int J Mol Med; 2008 Jan; 21(1):109-15. PubMed ID: 18097623
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors as novel anti-inflammatory agents.
Adcock IM
Curr Opin Investig Drugs; 2006 Nov; 7(11):966-73. PubMed ID: 17117583
[TBL] [Abstract][Full Text] [Related]
16. Response of retinoic acid-resistant KG1 cells to combination of retinoic acid with diverse histone deacetylase inhibitors.
Savickiene J; Treigyte G; Magnusson KE; Navakauskiene R
Ann N Y Acad Sci; 2009 Aug; 1171():321-33. PubMed ID: 19723072
[TBL] [Abstract][Full Text] [Related]
17. HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer.
López-Soto A; Folgueras AR; Seto E; Gonzalez S
Oncogene; 2009 Jun; 28(25):2370-82. PubMed ID: 19430493
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors and aspirin interact synergistically to induce cell death in ovarian cancer cells.
Sonnemann J; Hüls I; Sigler M; Palani CD; Hong le TT; Völker U; Kroemer HK; Beck JF
Oncol Rep; 2008 Jul; 20(1):219-24. PubMed ID: 18575740
[TBL] [Abstract][Full Text] [Related]
19. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMullan C; Miller JW; Marks PA; Mitsiades N
Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4072-9. PubMed ID: 19387079
[TBL] [Abstract][Full Text] [Related]
20. Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status.
Folkvord S; Ree AH; Furre T; Halvorsen T; Flatmark K
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):546-52. PubMed ID: 19427556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
